Bank of New York Mellon Corp Has $3.10 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Bank of New York Mellon Corp grew its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 43.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 244,829 shares of the company's stock after buying an additional 74,091 shares during the quarter. Bank of New York Mellon Corp owned 0.24% of Day One Biopharmaceuticals worth $3,102,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DAWN. Quest Partners LLC raised its position in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after buying an additional 7,668 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at approximately $324,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company's stock valued at $7,069,000 after purchasing an additional 64,700 shares during the last quarter. Algert Global LLC grew its holdings in shares of Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company's stock valued at $996,000 after purchasing an additional 50,990 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at approximately $174,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Day One Biopharmaceuticals Trading Down 1.2 %

DAWN traded down $0.10 during trading on Friday, reaching $8.23. 1,688,278 shares of the company's stock were exchanged, compared to its average volume of 1,085,064. Day One Biopharmaceuticals, Inc. has a one year low of $7.88 and a one year high of $18.07. The stock has a market capitalization of $834.15 million, a PE ratio of -7.99 and a beta of -1.38. The firm has a fifty day moving average price of $10.97 and a two-hundred day moving average price of $12.81.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts' expectations of $27.11 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. The trade was a 1.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. Company insiders own 8.40% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. HC Wainwright decreased their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Bank of America decreased their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. decreased their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $34.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.